Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Eugene Schneider, EVP and Chief Clinical Development Officer of Ionis Pharmaceuticals (IONS), reported option exercise and subsequent share sales executed on 09/03/2025. Schneider exercised a non-qualified stock option to acquire 19,658 shares at an exercise price of $53.77, which increased his beneficial ownership to 71,165 shares. He then sold 12,455 shares at a weighted average price of $60.4608, reducing ownership to 58,710, and sold an additional 7,203 shares at a weighted average price of $61.4163, bringing beneficial ownership to 51,507 shares. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on May 2, 2025. The Form 4 includes weighted-average price ranges for the sales and an undertaking to provide transaction price breakdowns on request.
Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals (IONS), reported a non-derivative purchase of 331 shares of Ionis common stock on 08/29/2025 at a price of $27.71 per share under the company's Amended and Restated 2000 Employee Stock Purchase Plan. After the purchase O'Neil beneficially owned 57,130 shares. The filing notes these ESPP-acquired shares may not be sold until 03/02/2026. The Form 4 is a single-person filing and reflects a routine employee-plan purchase rather than a sale or option exercise.
Brett Monia, who is listed as both a director and the Chief Executive Officer of Ionis Pharmaceuticals, purchased 189 shares of Ionis Pharmaceuticals, Inc. common stock on 08/29/2025 under the company’s Amended and Restated 2000 Employee Stock Purchase Plan at a per-share price of $27.71. Following the transaction the filing reports 180,009 shares beneficially owned. The purchased shares are subject to a sale restriction and may not be sold until 03/02/2026. The Form 4 was signed by an attorney-in-fact on behalf of Brett Monia on 09/03/2025.
Richard S. Geary, Executive Vice President and Chief Development Officer of Ionis Pharmaceuticals (IONS), reported a purchase of 165 shares of Ionis common stock on 08/29/2025 at a price of $27.71 per share under the company’s Amended and Restated 2000 Employee Stock Purchase Plan. After this transaction, he beneficially owns 89,657 shares directly. The reporting disclosure notes these purchased shares may not be sold until March 2, 2026, indicating a holding restriction tied to the plan.
C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals (IONS), reported an employee stock purchase on 08/29/2025. The filing shows 213 shares of Ionis common stock were acquired at a price of $27.71 under the company’s Amended and Restated 2000 Employee Stock Purchase Plan. Following the transaction the filing lists 93,679 shares beneficially owned (direct). The purchased shares are subject to a sale restriction and may not be sold until March 2, 2026. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Bennett on 09/03/2025.
Brian Birchler, EVP of Corporate and Development Operations at Ionis Pharmaceuticals (IONS), reported an insider purchase of 56,826 shares of Ionis common stock on 08/29/2025 at a price of $27.71 per share. The filing indicates these shares were acquired under the company’s Amended and Restated 2000 Employee Stock Purchase Plan and may not be sold until March 2, 2026. The Form 4 was executed by an attorney-in-fact and reflects that the shares are directly beneficially owned following the transaction.
Form 144 filed for Ionis Pharmaceuticals (IONS) reports a proposed sale of 16,000 shares of common stock via Stifel Nicolaus with an aggregate market value of $962,371.00. The filing lists approximately 159,391,229 shares outstanding and an approximate sale date of 09/03/2025 on Nasdaq. The shares were acquired by option exercise on 07/01/2016 and the proposed payment method is cash. The filer reports no securities sold in the past three months.
Ionis Pharmaceuticals (IONS) reported a Form 144 notice for a proposed sale of 124,850 shares of common stock to be handled by Stifel Nicolaus & Company, Inc. on 09/03/2025 on Nasdaq with an aggregate market value of $7,634,553.00. The shares were acquired on 01/04/2021 through an option exercise from the issuer and the planned consideration is cash. The filing also discloses a recent sale by Patrick O'Neil of 13,050 shares on 09/02/2025 for gross proceeds of $711,418.00. The filing includes the statutorily required declaration that the seller is not aware of undisclosed material adverse information.
Ionis Pharmaceuticals Form 144 notice: A proposed sale of 51,800 shares of common stock is reported to be executed through Stifel Nicolaus & Company, Inc. on 09/03/2025 with an aggregate market value of $3,152,698.00. The filing lists total shares outstanding of 159,391,229. Acquisition details for the shares to be sold are disclosed: 46,800 were acquired by option exercise on 01/03/2022, 7,537 were restricted stock units dated 01/15/2017, and 6,373 were restricted stock units dated 01/15/2016. The filing also reports sales by Frank Bennett in the past three months: 10,000 shares on 08/18/2025 for $439,776.00, and two sales on 09/02/2025 of 2,374 (proceeds $116,658.00) and 2,626 (proceeds $129,042.00). The filer signs a standard representation that no material nonpublic information is known. Other issuer contact and relationship fields are not populated in the provided content.
Ionis Pharmaceuticals (IONS) submitted a Form 144 notifying the proposed sale of 45,000 shares of common stock through Stifel Nicolaus & Company, with an aggregate market value of $2,658,996.00. The filing lists 159,391,229 shares outstanding and names Nasdaq as the exchange with an approximate sale date of 09/03/2025.
The securities were acquired by the seller on 01/31/2022 via an option exercise for 60,000 shares. The planned method of payment on sale is cash. The filing reports no securities sold by the person in the past three months and contains the standard attestation about absence of undisclosed material adverse information.